Your browser doesn't support javascript.
loading
MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in Malignancy.
Neupane, Manish; Clark, Allison P; Landini, Serena; Birkbak, Nicolai J; Eklund, Aron C; Lim, Elgene; Culhane, Aedin C; Barry, William T; Schumacher, Steven E; Beroukhim, Rameen; Szallasi, Zoltan; Vidal, Marc; Hill, David E; Silver, Daniel P.
Affiliation
  • Neupane M; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Clark AP; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Landini S; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Birkbak NJ; Center for Biological Sequence Analysis, Department of Systems Biology, Technical University of Denmark, Lyngby, Denmark.
  • Eklund AC; Center for Biological Sequence Analysis, Department of Systems Biology, Technical University of Denmark, Lyngby, Denmark.
  • Lim E; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia.
  • Culhane AC; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, and Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Barry WT; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, and Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Schumacher SE; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Beroukhim R; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts. Broad Institute of Harvard and MIT, Cambridge, Massachusetts. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Szallasi Z; Center for Biological Sequence Analysis, Department of Systems Biology, Technical University of Denmark, Lyngby, Denmark. Children's Hospital Informatics Program at the Harvard-MIT Division of Health Sciences and Technology, and Harvard Medical School, Boston, Massachusetts.
  • Vidal M; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. Center for Cancer Systems Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Genetics, Harvard Medical School, Boston, Massachusetts.
  • Hill DE; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. Center for Cancer Systems Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Genetics, Harvard Medical School, Boston, Massachusetts.
  • Silver DP; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Center for Cancer Systems Biology, Dana-Farber Cancer Institu
Cancer Discov ; 6(1): 45-58, 2016 Jan.
Article in En | MEDLINE | ID: mdl-26546296
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gene Amplification / Ras Proteins / Cytosine / Methyl-CpG-Binding Protein 2 / Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Cancer Discov Year: 2016 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Gene Amplification / Ras Proteins / Cytosine / Methyl-CpG-Binding Protein 2 / Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Cancer Discov Year: 2016 Document type: Article